Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Get the latest international news and world events from around the world.

Log in for authorized contributors

Inside the World’s First Age Reversal Trial | Lifespan with Dr. David Sinclair — S2, Ep. 4

At Lifespan, our mission is to help you and your loved ones live your longest, healthiest lives while supporting medical research into breakthroughs to improve all lives.

We’re building the world’s largest longevity community: Join us at https://lifespan.com.

Follow us on YouTube, Apple, and Spotify for new Lifespan episodes every 2 weeks.

In this episode of Lifespan, Dr. David Sinclair, A.O., Ph.D. – Professor of Genetics at Harvard Medical School and pioneer in longevity research – explores the science of eye aging, vision loss, and emerging strategies to preserve vision throughout life.

Dr. Sinclair shares an inside update on ER-100, including his team’s successful restoration of vision in non-human primates and the launch of the world’s first FDA-cleared age reversal human clinical trial. This Phase 1 clinical trial will evaluate the safety of epigenetic cellular restoration as a therapy.

Additionally, drawing on decades of research, Dr. Sinclair explains why the eyes may offer one of the earliest windows into biological aging, how everyday factors such as sleep position, alcohol consumption, and intraocular pressure influence long-term eye health, and what the latest evidence reveals about nutrition, supplements, and the connection between the eyes and the brain.

Continue reading “Inside the World’s First Age Reversal Trial | Lifespan with Dr. David Sinclair — S2, Ep. 4” | >

Why the Next 10 Years May Add 50 to Your Lifespan | Dr. Derya Unutmaz

The next 10 years may add decades to human lifespan by compressing the time it takes to understand, treat, and prevent disease. In this episode, Dr. Derya Unutmaz explains why accelerating AI could transform drug discovery, shorten clinical trials, and push cancer treatment toward increasingly personalized interventions. He also reframes AI not as an existential threat, but as a medical enabler that doctors may soon be ethically obligated to use.

Get weekly, protocol-driven research breakdowns from Dr. Rhonda Patrick to advance healthspan, longevity, brain health, and resilience: https://www.foundmyfitness.com/newsle… 00:00:00 Introduction 00:02:16 Why the next 10 years may add 50 to your lifespan 00:06:25 How AI is transforming drug discovery 00:11:55 Could digital twins shorten clinical trials? 00:14:31 Can AI predict drug safety and efficacy? 00:18:46 Have we already reached AGI? 00:24:28 Why AI may be medicine’s greatest force multiplier 00:30:41 Can AI replicate a scientist’s biological intuition? 00:37:22 Is it malpractice for doctors not to use AI? 00:43:24 What happens when AI monitors disease in real time? 00:46:58 Which AI models should doctors trust? 00:52:34 Claude vs. GPT—does the model matter for diagnosis? 00:56:04 Generalist vs. specialized AI—which works better in medicine? 00:59:30 Why cancer is so hard to cure 01:03:24 Could cancer be curable within a decade? 01:07:35 Can AI design cancer treatments on demand? 01:09:37 How AI could curb overtreatment and side effects 01:12:33 Predicting cancer years before it forms—is it possible? 01:18:55 Why biology could go exponential with AI 01:24:04 Why aging may be easier to prevent than reverse 01:29:56 Can the body be engineered to resist aging? 01:35:13 Can AI model how gene therapy will behave? 01:39:17 What people who reach 110+ reveal about Human 2.0 01:41:27 From Dolly to Yamanaka factors—the case for cellular age reversal 01:46:02 Why full-body rejuvenation is an engineering problem 01:53:49 What happens when AI reasons longer about biology? 01:56:31 The biosecurity dilemma of powerful AI 02:01:17 What should we actually measure to track aging? 02:07:40 How old immune cells distort aging clocks 02:10:28 Why reversing brain aging is uniquely difficult 02:16:55 The ultimate prompt for extending lifespan 02:18:56 What data does a true digital twin need? 02:23:38 How to build a mini digital twin today 02:28:32 How to give AI a long-term memory of your data 02:31:39 Why personal baselines matter for AI advice Derya Unutmaz, M.D. X: https://twitter.com/DeryaTR_ EPISODE LINKS Show notes & transcript: https://www.foundmyfitness.com/episod… PODCAST INFO Apple Podcasts: https://podcasts.apple.com/us/podcast… Spotify: https://open.spotify.com/episode/4BPh… SUPPORT MY MISSION Access more than 130 episodes of my premium podcast (The Aliquot) when you become a FoundMyFitness Premium Member: https://www.foundmyfitness.com/crowds… #ai.

CHAPTERS:
00:00:00 Introduction.
00:02:16 Why the next 10 years may add 50 to your lifespan.
00:06:25 How AI is transforming drug discovery.
00:11:55 Could digital twins shorten clinical trials?
00:14:31 Can AI predict drug safety and efficacy?
00:18:46 Have we already reached AGI?
00:24:28 Why AI may be medicine’s greatest force multiplier.
00:30:41 Can AI replicate a scientist’s biological intuition?
00:37:22 Is it malpractice for doctors not to use AI?
00:43:24 What happens when AI monitors disease in real time?
00:46:58 Which AI models should doctors trust?
00:52:34 Claude vs. GPT—does the model matter for diagnosis?
00:56:04 Generalist vs. specialized AI—which works better in medicine?
00:59:30 Why cancer is so hard to cure.
01:03:24 Could cancer be curable within a decade?
01:07:35 Can AI design cancer treatments on demand?
01:09:37 How AI could curb overtreatment and side effects.
01:12:33 Predicting cancer years before it forms—is it possible?
01:18:55 Why biology could go exponential with AI
01:24:04 Why aging may be easier to prevent than reverse.
01:29:56 Can the body be engineered to resist aging?
01:35:13 Can AI model how gene therapy will behave?
01:39:17 What people who reach 110+ reveal about Human 2.0
01:41:27 From Dolly to Yamanaka factors—the case for cellular age reversal.
01:46:02 Why full-body rejuvenation is an engineering problem.
01:53:49 What happens when AI reasons longer about biology?
01:56:31 The biosecurity dilemma of powerful AI
02:01:17 What should we actually measure to track aging?
02:07:40 How old immune cells distort aging clocks.
02:10:28 Why reversing brain aging is uniquely difficult.
02:16:55 The ultimate prompt for extending lifespan.
02:18:56 What data does a true digital twin need?
02:23:38 How to build a mini digital twin today.
02:28:32 How to give AI a long-term memory of your data.
02:31:39 Why personal baselines matter for AI advice.

Derya Unutmaz, M.D.
X: https://twitter.com/DeryaTR_

EPISODE LINKS
Show notes & transcript: https://www.foundmyfitness.com/episod…

Scientists discover a compound that could supercharge aging muscle repair

However, additional studies involving aging animals will be required to determine whether LASSS is safe and effective in vivo.

A Possible Strategy for Preserving Muscle

The discovery could support the development of new approaches for maintaining muscle repair during aging, extended bed rest, and other conditions that involve long periods of inactivity.

Drug discovery Is changing. Drug development must change too

💬 Artificial intelligence and big data are flooding discovery pipelines with high-potential drug candidates, but this rapid innovation has created a new challenge. Simply put, our capability to design miracle molecules is vastly outstripping our technology to mass-manufacture them safely for the global public. Moving drug making from the scale of lab flasks to commercial bioreactors introduces non-linear biological and engineering shifts that can undermine tasks like purification.

⚡In this New Scientist CoLab podcast, experts from global life sciences leader Cytiva explain the hidden, high-stakes science of purification that is required to close the gap between drug discovery and the pharmacy shelf.

Charlie Stross: The World is Complicated. Elegant Narratives Explaining Everything Are Wrong!

Fifteen years ago, I interviewed Charlie Stross about a short story called “Lobsters.”

This spring, a thousand people queued outside Tencent’s Shenzhen headquarters to raise one.

June 2011, Singularity 1 on 1. Back then, “singularity” was a word most people filed under astrophysics, not #AI. Charlie’s 2001 story “Lobsters,” which grew into Accelerando, was one of the sharpest early maps of what happens when intelligence stops being exclusively biological. Uploaded minds. Post-scarcity economics. Legal personhood for software. An economy run by optimization processes no human fully follows.

He wrote it six years before the iPhone.

Now look at 2026. OpenClaw, the open source agent built by Austrian developer Peter Steinberger, now at OpenAI, became the fastest-growing project in GitHub history. In China, installing it is called 养龙虾, “raising lobsters,” after the red logo. Shenzhen, Wuxi and Changshu rushed out subsidy packages. Retirees, schoolkids and office workers lined up for help. A grey market of house-call technicians appeared within days.

Any connection to Charlie’s story? None. The logo is a claw pun on Claude.

Continue reading “Charlie Stross: The World is Complicated. Elegant Narratives Explaining Everything Are Wrong!” | >

AI & Quantum Computing Are Redefining Research & Development, Manufacturing & Technological Exploration

Chuck Brooks is the president of Brooks Consulting International and one of Executive Mosaic’s GovCon Experts.

The convergence of AI and quantum tech is creating a new frontier of innovation and risk.

This trend is evident from the White House’s FY27 research and development goals that put Artificial intelligence and quantum technologies at the center of the national agenda.

Gene activity in blood fluctuates more than expected—and that has consequences for medicine

Take a blood sample from someone in the dead of winter. Take another in midsummer. Same person, same laboratory. And yet, at the level of gene activity, the molecular picture can look surprisingly different. This is not an anomaly. This, a new Nature Communications study argues, is simply how human biology works, and it has significant implications for the way biomarkers have traditionally been studied.

Researchers from Kiel University’s Excellence Cluster PMI, KU Leuven and the German Center for Neurodegenerative Diseases (DZNE) in Bonn tracked 333 volunteers in Flanders over six months, drawing blood three times and measuring the activity of roughly 14,000 genes on each occasion.

What they found suggests that an important source of biological variation has been underappreciated in many clinical studies: in 85% of all genes, the variation within a single person over time is larger than the variation between different people. In other words, for most genes, the largest differences are observed between two time points in the same individual rather than between different individuals.

From one frontier to another: The quantum revolution

Manchester’s quantum researchers are building on the Ferranti Mark I legacy, using ultra-pure silicon and single atoms to move quantum computing closer to real-world impact.

In February 1951, a machine the size of a room arrived at the University of Manchester.

The Ferranti Mark I, the world’s first commercially available general-purpose computer, came with 4,000 vacuum tubes, 100,000 soldered joints and six miles (10 kilometers) of wires. The 27 kilowatts of power it needed to operate is the equivalent of running roughly 600 midrange laptops today, yet at the time, it must have felt miraculous.

/* */